Article Information
History
- September 8, 2020.
Article Versions
- Version 1 (August 6, 2020 - 03:24).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Gido Snaterse1,a,
- Lisanne F van Dessel2,a,
- Angela E Taylor3,
- Jenny A Visser1,
- Wiebke Arlt3,
- Martijn P Lolkema2 and
- Johannes Hofland1,*
- 1Department of Internal Medicine, Section of Endocrinology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
- 2Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
- 3Institute of Metabolism and System Research, University of Birmingham, Birmingham, United Kingdom
- ↵* Corresponding author Address for correspondence: Johannes Hofland, Department of Internal Medicine, Erasmus MC, Rg5, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands. Tel.: +31 10 704 0446. E-mail: j.hofland{at}erasmusmc.nl
↵a These authors contributed equally to this work.
Posted September 08, 2020.
Validation of multiplex steroid hormone measurements in prostate cancer using plasma for multimodality biomarker studies
